TITLE

Life threatening haemoptysis in cystic fibrosis: an alternative therapeutic approach

AUTHOR(S)
Bilton, D; Webb, A K; Foster, H; Mulvenna, P; Dodd, M
PUB. DATE
December 1990
SOURCE
Thorax;Dec1990, Vol. 45 Issue 12, p975
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66101489

 

Related Articles

  • Targeted therapies to improve CFTR function in cystic fibrosis. Brodlie, Malcolm; Haq, Iram J.; Roberts, Katie; Elborn, J. Stuart // Genome Medicine;9/25/2015, Vol. 7 Issue 1, p1 

    Cystic fibrosis is the most common genetically determined, life-limiting disorder in populations of European ancestry. The genetic basis of cystic fibrosis is well established to be mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that codes for an apical membrane...

  • BAB, Inc. to Support Fundraising for Cystic Fibrosis Foundation.  // Biomedical Market Newsletter;5/14/2011, p718 

    The article reports that the firm BAB Inc. is supporting fundraising for Cystic Fibrosis Foundation. It announces that a national 65 Roses campaign with the Cystic Fibrosis Foundation will be launched on April 8, 2011 in which BAB will be selling their 65 Roses mugs. Further it focuses on the...

  • Treatment massive haemoptysis in cystic fibrosis with tranexamic acid. Hurley, Matthew; Bhatt, Jayesh; Smyth, Alan // Journal of the Royal Society of Medicine (Supplement);Jul2011, Vol. 104 Issue 1, pS49 

    The article presents a case study of a ten year old boy with cystic fibrosis who received intravenous antibiotics every four months and who experienced a massive haemoptysis after an episode of increased coughing. A discussion of treatment which the patient received for his haemoptysis with...

  • A therapeutic conundrum: recurrent cystic-fibrosis-related haemoptysis complicated by acute pulmonary embolism. Flight, William G.; Bright-Thomas, Rowland J.; Butterfield, Stephen; Jones, Andrew M.; Webb, A. Kevin // Thorax;Oct2012, Vol. 67 Issue 10, p931 

    The authors present the case of an older patient with cystic fibrosis (CF) and recurrent haemoptysis complicated by acute pulmonary embolism. The patient was treated successfully with a combination of anticoagulation and bronchial artery embolisation. The management of CF-related haemoptysis,...

  • Identification of Synergistic Combinations of F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. Stephen Lin; Jinliang Sui; Shakira Cotard; Brenda Fung; Jennifer Andersen; Ping Zhu; Najib El Messadi; Joseph Lehar; Margaret Lee; Jane Staunton // Assay & Drug Development Technologies;Dec2010, Vol. 8 Issue 6, p669 

    AbstractCystic fibrosis (CF) is an inherited, life-threatening disease caused by mutations in the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR), an ABC transporter-class protein and ion channel that transports ions across epithelial cell membranes. The most common...

  • Radiological intervention for haemoptysis in cystic fibrosis. Ashleigh, R. J.; Webb, A. K. // Journal of the Royal Society of Medicine (Supplement);Jun2007, Vol. 100 Issue 47, p38 

    The article discusses the use of trans-arterial embolization in the treatment of a common cystic fibrosis (CF) complication called haemoptysis. Classifications of haemoptysis is also presented which include massive haemoptysis which can lead to asphyxiation and non-massive haemoptysis where...

  • US guidelines for treating complications of CF released.  // PharmacoEconomics & Outcomes News;9/18/2010, Issue 612, p4 

    The article reports that the Cystic Fibrosis (CF) Foundation Pulmonary Therapies Committee, U.S., has released guidelines for managing complications of CF, specifically haemoptysis and pneumothorax.

  • Pre-hospital management of cystic fibrosis patients presenting with haemoptysis. Sofianopoulos, Sarah; Williams, Brett // Journal of Paramedic Practice;Mar2013, Vol. 5 Issue 3, p139 

    This paper discusses the pre-hospital clinical management of cystic fibrosis (CF) patients suffering with haemoptysis. While clear guidelines and procedures exist within hospitals in regard to the management of such patients, the same cannot be said for the pre-hospital setting, with very...

  • Optimization of a Yellow Fluorescent Protein-Based Iodide Influx High-Throughput Screening Assay for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. Jinliang Sui; Shakira Cotard; Jennifer Andersen; Ping Zhu; Jane Staunton; Margaret Lee; Stephen Lin // Assay & Drug Development Technologies;Dec2010, Vol. 8 Issue 6, p656 

    AbstractCystic fibrosis is an inherited, life-threatening disease associated with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The most common mutation, F508del CFTR, is found in 90% of CF patients. The loss of a single amino acid (phenylalanine at position...

  • Cystic fibrosis breath test spots deadly infection.  // GP: General Practitioner;10/28/2005, p4 

    This article informs that according to U.S. and German research, a breath test for patients with cystic fibrosis could show whether they have developed a potentially life-threatening lung infection. The study included 20 patients with mild-to-moderate cystic fibrosis and 23 healthy patients. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics